NEDD4L and neoplasm: In another study, NEDD4L targets the RSPO receptor LGR4/5 and DVL2 for degradation to inactivate the WNT/β-catenin signaling pathway and attenuate intestinal stem cell priming, leading to tumor predisposition and progression inhibition [36].